بدائل البحث:
largest decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
_ largest » _ large (توسيع البحث)
largest decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
_ largest » _ large (توسيع البحث)
-
1
-
2
-
3
Data and code from: Continental declines in North American small mammal populations
منشور في 2025الموضوعات: -
4
-
5
-
6
-
7
Univariate and Multivariate analysis of risk factors for nerve injury 90-days after TKA.
منشور في 2025الموضوعات: -
8
-
9
-
10
-
11
-
12
Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses
منشور في 2025الموضوعات: -
13
-
14
Table 5_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"
-
15
Table 1_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"
-
16
Table 4_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"
-
17
Table 3_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"
-
18
Table 6_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"
-
19
Table 2_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"
-
20
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
منشور في 2025"…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"